约70%的上皮性卵巢癌患者确诊时已属晚期。当无法进行初次最佳手术时，新辅助化疗后进行中间减瘤手术是其中一种治疗选择。然而，对于手术的最佳时机并无共识。CA125是卵巢癌中众所周知的肿瘤标志物。

适应症：Ovarian Cancer、Fallopian Tube Cancer、Peritoneal Cancer

入组条件

Patients must be at least 18 years old.
Patients who have Eastern Cooperative Oncology Group (ECOG) score 0-1.
Patients who are competent to give informed consent.
Patients who have stage III-IV histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube or primary peritoneal cancer not amenable for primary debulking surgery (PDS).
Patients who are planned for neoadjuvant chemotherapy (NACT) using platinum-based chemotherapy +/- bevacizumab or biosimilar. Those who are receiving NACT before interval debulking surgery (IDS) are also eligible.
Patients who have an evaluable CA125 level at baseline (i.e., baseline level is at least 2x upper limit of normal).
Patients who have baseline computed tomography of at least abdomen and pelvis, or positron emission tomography (PET)-CT. Magnetic resonance imaging (MRI) is also acceptable but the same modality has to be used when assessing the feasibility of IDS.
Patients who agree to undergo IDS, where the time of IDS may differ from the usual clinical practice.
Patients who agree to receive adjuvant chemotherapy, if clinically indicated. The total number of chemotherapy should be at least four or above.

Patients who have borderline malignancy, or non-epithelial ovarian cancer like germ cell or sex cord tumor, or metastatic diseases from other origins like Krukenberg's tumor
Patients who are eligible for PDS
Patients who are not fit for PDS because of medical morbidities or refusal of operation
Patients who have already started NACT outside the study centres, except those who have just had one cycle within 21 days and the baseline CA125 is available.
Patients who are pregnant

入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。

晚期卵巢癌中间减瘤手术的个人化时机